In the secondary analysis, the much less conservative but clinically meaningful criterion of stable reaction (outlined for a fifty% or more reduction in MADRS from baseline for 2 months) was used. From the patients who realized stable reaction, 25.8% while in the esketamine group and 57.six% in the placebo group https://meherv000per7.wikifiltraciones.com/user